Cipla Q2 Results 2025 Highlights: Net Profit Rises by 3.73% & Revenue Up 7.64% YoY

October 31, 2025
Posted by: sachet
Category: News

Click and Sign Up to Get Live Updates on Q2 Results

Cipla Q2 Results FY26: During Q2 FY26, Cipla’s profit increased 3.73% YoY, while revenue increased by 7.64% YoY. The company posted robust numbers, with Q2 PAT at ₹1,351.17 crores and revenue at ₹7,589.44 crores. Cipla showed its Q2 results on 30th October 2025.

Table of Contents

Cipla Q2 Results FY26: Extracts of FY25 & FY26

Particulars	Consolidated Figures		Standalone Figures
	30th Sep 2025	30 Sept 2024	30th Sept 2025	30th Sept 2024
Revenue from Operations	₹7,589.44	₹7,051.02	₹5,225.72	₹4,775.03
Profit Before Tax (PBT)	₹2,163.70	₹2,076.20	₹1,777.29	₹1,727.18
Profit After Tax (PAT)	₹1,351.17	₹1,302.53	₹1,210.53	₹1,178.16

Cipla Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

Cipla clocked Q2 FY26 consolidated revenue of ₹7,589.44 crores vs ₹7,051.02 crores.
On the profit front, Cipla earned a consolidated PAT of ₹1,351.17 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹1,302.53 crore.
According to the consolidated figures, Cipla’s quarterly PAT increased by 3.73% YoY, while revenue increased by 7.64%.
Cipla clocked Q2 FY26 standalone revenue of ₹5,225.72 crores vs ₹4,775.03 crores.
On the profit front, Cipla earned a standalone PAT of ₹1,210.53 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹1,178.16 crore.
According to the standalone figures, Cipla’s quarterly PAT increased by 2.75% YoY, while revenue increased by 9.44%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

About Cipla Limited

Cipla was established in 1935, with its headquarters in 1965. It is an Indian multinational pharmaceutical company that develops and manufactures a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and generic drugs. The company has a global presence in over 80 countries and a diverse product portfolio exceeding 1,500 products. The company has a significant focus on respiratory and HIV/AIDS treatments. The company has a global presence in Africa, North America and India.

Cipla Share Price Performance

On the opening bell on 31st October 2025, Cipla shares opened at ₹1,516.10 per share. However, the initial gains have since eroded, and Cipla shares are trading at ₹1,509.10 per share, below the opening price.

Considering the long-term achievements, Cipla shares have yielded returns of approximately -2.68% over the past 6 months, and 1-year returns stand at -2.84%. Over the maximum timeframe, Cipla shares delivered a 6,325.22% return to investors.

What Analysts Expect Post Q2 Results?

Following Cipla’s robust Q2 results, analysts expect its share price to rise. According to analysts, Cipla’s share price could reach ₹1,630.20 per share in the coming year and, in a downturn, could fall to ₹ 1,490.20 per share. However, one must ignore stock market volatility and invest in Cipla’s shares after thorough research.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.